alanine has been researched along with Colorectal Neoplasms in 22 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with metastatic colorectal cancer previously treated with combination chemotherapy were randomly assigned 1:1 to receive cetuximab 400 mg/m(2) intravenous loading dose followed by weekly maintenance of 250 mg/m(2) plus either brivanib 800 mg orally daily (arm A) or placebo (arm B)." | 9.17 | Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr ( Charpentier, D; Couture, F; Haydon, A; Jefford, M; Jonker, DJ; Karapetis, CS; Liauw, W; Magoski, NM; Moore, MJ; Nott, LM; O'Callaghan, CJ; Price, TJ; Ringash, J; Sawyer, MB; Shapiro, JD; Siddiqui, J; Simes, J; Siu, LL; Tu, D; Walters, I; Zalcberg, JR, 2013) |
| "Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line treatments of metastatic colorectal cancer." | 8.90 | A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. ( Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P, 2014) |
| "We tested these hypotheses among participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned to placebo or to aspirin treatment (81 or 325 mg daily) and followed for 3 years for the occurrence of new adenomas." | 7.73 | Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. ( Ahnen, DJ; Baron, JA; Barry, EL; Bhat, S; Burke, CA; Grau, MV; Haile, RW; O'Brien, TG; Sandler, RS, 2006) |
| "20 trial randomized patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET/placebo)." | 5.19 | Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. ( Alcindor, T; Au, HJ; Easaw, JC; El-Tahche, F; Jeffery, M; Jonker, DJ; Kotb, R; Moore, MJ; Ng, S; O'Callaghan, CJ; Ringash, J; Sabesan, S; Salim, M; Shannon, J; Shapiro, JD; Siu, LL; Strickland, A; Tu, D; Walters, I; Zalcberg, JR, 2014) |
| "Patients with metastatic colorectal cancer previously treated with combination chemotherapy were randomly assigned 1:1 to receive cetuximab 400 mg/m(2) intravenous loading dose followed by weekly maintenance of 250 mg/m(2) plus either brivanib 800 mg orally daily (arm A) or placebo (arm B)." | 5.17 | Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr ( Charpentier, D; Couture, F; Haydon, A; Jefford, M; Jonker, DJ; Karapetis, CS; Liauw, W; Magoski, NM; Moore, MJ; Nott, LM; O'Callaghan, CJ; Price, TJ; Ringash, J; Sawyer, MB; Shapiro, JD; Siddiqui, J; Simes, J; Siu, LL; Tu, D; Walters, I; Zalcberg, JR, 2013) |
| "Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line treatments of metastatic colorectal cancer." | 4.90 | A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. ( Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P, 2014) |
| " Blood samples were collected from 20 patients, who had received continuous intravenous infusion (CIV) of 5-FU (320 mg/m2/24 hr) after resection of colorectal cancer, and the FBAL level was determined by high performance liquid chromatography (HPLC), after derivatizing into o-phthalaldehyde (OPA) and detecting fluorescence." | 3.73 | Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kawakami, M; Kihara, C; Kimura, Y; Ohmura, T; Okita, K; Sasaki, K; Tsuruma, T; Yamaguchi, K, 2006) |
| "We tested these hypotheses among participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned to placebo or to aspirin treatment (81 or 325 mg daily) and followed for 3 years for the occurrence of new adenomas." | 3.73 | Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. ( Ahnen, DJ; Baron, JA; Barry, EL; Bhat, S; Burke, CA; Grau, MV; Haile, RW; O'Brien, TG; Sandler, RS, 2006) |
| "A network meta-analysis was conducted comparing the short-term efficacies of 16 targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer (CRC)." | 2.53 | A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer. ( Ba-Sang, DZ; Li, MS; Long, ZW; Qiu, J; Teng, H; Zhao, XP, 2016) |
| "Although colorectal cancer (CRC) is considered one of the most preventable cancers, no non-invasive, accurate diagnostic tool to screen CRC exists." | 1.51 | Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer. ( Kim, ER; Kim, JJ; Kim, YH; Kwon, HN; Nam, H; Park, S, 2019) |
| "Part of the inherited susceptibility to colorectal cancer (CRC) is caused by the coinheritance of common low risk variants." | 1.35 | The CDH1-160C>A polymorphism is a risk factor for colorectal cancer. ( Broderick, P; Chandler, I; Houlston, RS; Lubbe, S; Penegar, S; Pittman, AM; Twiss, P, 2009) |
| "We analyzed 92 colorectal cancers (CRCs) and 57 cancer cell lines (representing a diversity of tumor types) to determine the frequency of activating mutations in this gene." | 1.30 | Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. ( DeNobile, JW; Dimond, E; Grogan, L; Hausner, P; Kirsch, IR; Kitaeva, MN; Nakahara, K; Soballe, PW; Williams, JP, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, N | 1 |
| Kawano, Y | 1 |
| Sakai, H | 1 |
| Hayashi, S | 1 |
| Akizuki, N | 1 |
| Komoda, M | 1 |
| Hanawa, T | 1 |
| Wang, F | 1 |
| Song, ZY | 1 |
| Qu, XJ | 1 |
| Li, F | 1 |
| Zhang, L | 1 |
| Li, WB | 1 |
| Cui, SX | 1 |
| Shepshelovich, D | 1 |
| Townsend, AR | 1 |
| Espin-Garcia, O | 1 |
| Latifovic, L | 1 |
| O'Callaghan, CJ | 4 |
| Jonker, DJ | 4 |
| Tu, D | 4 |
| Chen, E | 1 |
| Morgen, E | 1 |
| Price, TJ | 3 |
| Shapiro, J | 1 |
| Siu, LL | 4 |
| Kubo, M | 1 |
| Dobrovic, A | 1 |
| Ratain, MJ | 1 |
| Xu, W | 1 |
| Mushiroda, T | 1 |
| Liu, G | 2 |
| Wells, JC | 1 |
| Shapiro, JD | 3 |
| Karapetis, C | 1 |
| Simes, J | 2 |
| Tebbutt, NC | 1 |
| Kim, ER | 1 |
| Kwon, HN | 1 |
| Nam, H | 1 |
| Kim, JJ | 1 |
| Park, S | 1 |
| Kim, YH | 1 |
| Karapetis, CS | 1 |
| Zalcberg, JR | 2 |
| Couture, F | 1 |
| Moore, MJ | 2 |
| Siddiqui, J | 1 |
| Nott, LM | 1 |
| Charpentier, D | 1 |
| Liauw, W | 1 |
| Sawyer, MB | 1 |
| Jefford, M | 1 |
| Magoski, NM | 1 |
| Haydon, A | 1 |
| Walters, I | 2 |
| Ringash, J | 2 |
| Au, HJ | 1 |
| Strickland, A | 1 |
| Kotb, R | 1 |
| Jeffery, M | 1 |
| Alcindor, T | 1 |
| Ng, S | 1 |
| Salim, M | 1 |
| Sabesan, S | 1 |
| Easaw, JC | 1 |
| Shannon, J | 1 |
| El-Tahche, F | 1 |
| Nielsen, DL | 1 |
| Palshof, JA | 1 |
| Larsen, FO | 1 |
| Jensen, BV | 1 |
| Pfeiffer, P | 1 |
| Ba-Sang, DZ | 1 |
| Long, ZW | 1 |
| Teng, H | 1 |
| Zhao, XP | 1 |
| Qiu, J | 1 |
| Li, MS | 1 |
| Pittman, AM | 1 |
| Twiss, P | 1 |
| Broderick, P | 1 |
| Lubbe, S | 1 |
| Chandler, I | 1 |
| Penegar, S | 1 |
| Houlston, RS | 1 |
| Boleij, A | 1 |
| Dutilh, BE | 1 |
| Kortman, GA | 1 |
| Roelofs, R | 1 |
| Laarakkers, CM | 1 |
| Engelke, UF | 1 |
| Tjalsma, H | 1 |
| Levine, AJ | 1 |
| Elkhouly, E | 1 |
| Diep, AT | 1 |
| Lee, ER | 1 |
| Frankl, H | 1 |
| Haile, RW | 2 |
| Masaki, T | 1 |
| Sugiyama, M | 1 |
| Matsuoka, H | 1 |
| Abe, N | 1 |
| Izumisato, Y | 1 |
| Goto, A | 1 |
| Sakamoto, A | 1 |
| Atomi, Y | 1 |
| Fuszek, P | 1 |
| Lakatos, P | 1 |
| Tabák, A | 1 |
| Papp, J | 1 |
| Nagy, Z | 1 |
| Lakatos, PL | 1 |
| Speer, G | 1 |
| Gong, Z | 1 |
| Xie, D | 1 |
| Deng, Z | 1 |
| Bostick, RM | 1 |
| Muga, SJ | 1 |
| Hurley, TG | 1 |
| Hebert, JR | 1 |
| Jiang, J | 1 |
| Gajalakshmi, V | 1 |
| Wang, J | 1 |
| Kuriki, K | 1 |
| Suzuki, S | 1 |
| Nakamura, S | 1 |
| Akasaka, S | 1 |
| Ishikawa, H | 1 |
| Tokudome, S | 1 |
| Debniak, T | 1 |
| Scott, RJ | 1 |
| Huzarski, T | 1 |
| Byrski, T | 1 |
| Rozmiarek, A | 1 |
| Debniak, B | 1 |
| Górski, B | 1 |
| Cybulski, C | 1 |
| Medrek, K | 1 |
| Mierzejewski, M | 1 |
| Masojc, B | 1 |
| Matyjasik, J | 1 |
| Złowocka, E | 1 |
| Teodorczyk, U | 1 |
| Lener, M | 1 |
| Klujszo-Grabowska, E | 1 |
| Nej-Wołosiak, K | 1 |
| Jaworowska, E | 1 |
| Oszutowska, D | 1 |
| Szymańska, A | 1 |
| Szymańska, J | 1 |
| Castaneda, J | 1 |
| van de Wetering, T | 1 |
| Suchy, J | 1 |
| Kurzawski, G | 1 |
| Oszurek, O | 1 |
| Narod, S | 1 |
| Lubinski, J | 1 |
| Furuhata, T | 1 |
| Kawakami, M | 1 |
| Okita, K | 1 |
| Kimura, Y | 1 |
| Kihara, C | 1 |
| Tsuruma, T | 1 |
| Ohmura, T | 1 |
| Yamaguchi, K | 1 |
| Hata, F | 1 |
| Katsuramaki, T | 1 |
| Sasaki, K | 1 |
| Hirata, K | 1 |
| Barry, EL | 1 |
| Baron, JA | 1 |
| Bhat, S | 1 |
| Grau, MV | 1 |
| Burke, CA | 1 |
| Sandler, RS | 1 |
| Ahnen, DJ | 1 |
| O'Brien, TG | 1 |
| Hollestelle, MJ | 1 |
| Timmerman, P | 1 |
| Meloen, RH | 1 |
| Höppener, JW | 1 |
| Kitaeva, MN | 1 |
| Grogan, L | 1 |
| Williams, JP | 1 |
| Dimond, E | 1 |
| Nakahara, K | 1 |
| Hausner, P | 1 |
| DeNobile, JW | 1 |
| Soballe, PW | 1 |
| Kirsch, IR | 1 |
| Slansky, JE | 1 |
| Rattis, FM | 1 |
| Boyd, LF | 1 |
| Fahmy, T | 1 |
| Jaffee, EM | 1 |
| Schneck, JP | 1 |
| Margulies, DH | 1 |
| Pardoll, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination With Cetuximab (Erbitux®) Versus Placebo in Combination With Cetuximab (Erbitux®) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for M[NCT00640471] | Phase 3 | 750 participants (Actual) | Interventional | 2008-05-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for alanine and Colorectal Neoplasms
| Article | Year |
|---|---|
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Topics: Alanine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2014 |
A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.
Topics: Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2016 |
3 trials available for alanine and Colorectal Neoplasms
| Article | Year |
|---|---|
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
Topics: Aged; Alanine; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Female; Humans; Male; Middle | 2018 |
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr
Topics: Adult; Aged; Alanine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.
Topics: Alanine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuxima | 2014 |
17 other studies available for alanine and Colorectal Neoplasms
| Article | Year |
|---|---|
Effects of a Rebamipide Mouthwash on Stomatitis Caused by Cancer Chemotherapy-Evaluation of the Efficacy by Patients Themselves.
Topics: Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Colorectal Neoplasms; Humans; Lung Neoplasm | 2017 |
M10, a novel derivative of Myricetin, prevents ulcerative colitis and colorectal tumor through attenuating robust endoplasmic reticulum stress.
Topics: Alanine; Animals; Anticarcinogenic Agents; Colitis, Ulcerative; Colon; Colorectal Neoplasms; Disease | 2018 |
Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.
Topics: Age Factors; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Tria | 2019 |
Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Alanine; Aminoisobutyric Acids; Biomarkers, Tumor; Colorect | 2019 |
The CDH1-160C>A polymorphism is a risk factor for colorectal cancer.
Topics: Aged; Alanine; Antigens, CD; Cadherins; Case-Control Studies; Colorectal Neoplasms; Cysteine; Female | 2009 |
Bacterial responses to a simulated colon tumor microenvironment.
Topics: Adenocarcinoma; Alanine; Bacterial Proteins; Cell Line, Tumor; Colon; Colorectal Neoplasms; Culture | 2012 |
The MnSOD A16V mitochondrial targeting sequence polymorphism is not associated with increased risk of distal colorectal adenomas: data from a sigmoidoscopy-based case control study.
Topics: Adenoma; Aged; Alanine; alpha-Tocopherol; Antioxidants; Case-Control Studies; Codon; Colorectal Neop | 2002 |
Clinical utility of grading criteria for submucosal invasion in the prognosis of T1 colorectal carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Alanine; alpha Catenin; Cadherins; Colorectal Neoplasms; Cytoskeleta | 2003 |
[Significance of serum calcium levels in colorectal cancer].
Topics: Aged; Alanine; Biomarkers, Tumor; CA-19-9 Antigen; Calcium; Colorectal Neoplasms; Female; Genotype; | 2004 |
The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Alanine; Colorectal Neoplasms; Female; Heterozygote; Humans; Male; Middle Aged | 2005 |
Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population.
Topics: Adult; Aged; Alanine; Colonic Neoplasms; Colorectal Neoplasms; Cytosine; Gene Frequency; Haplotypes; | 2005 |
CDKN2A common variant and multi-organ cancer risk--a population-based study.
Topics: Adult; Aged; Alanine; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Female; Genes, p1 | 2006 |
Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients.
Topics: Aged; Alanine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Combined Modality Therapy | 2006 |
Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.
Topics: Adenoma; Adenomatous Polyposis Coli; Aged; Alanine; Anticarcinogenic Agents; Aspirin; Colorectal Neo | 2006 |
Characterization of gastrin-cholecystokinin 2 receptor interaction in relation to c-fos induction.
Topics: Alanine; Amino Acid Substitution; Animals; Cell Proliferation; Colorectal Neoplasms; DNA Primers; Ga | 2008 |
Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors.
Topics: Adult; Aged; Alanine; Amino Acid Substitution; Base Sequence; beta Catenin; Cadherins; Colorectal Ne | 1997 |
Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex.
Topics: Alanine; Amino Acid Substitution; Animals; Antigens, Neoplasm; Clone Cells; Colorectal Neoplasms; Cy | 2000 |